PharmAla Overhauls Board with Financial Executive as MDMA Research Ramps Up

Event summary

  • PharmAla Biotech replaced Dr. Malik Slassi with Lennie Ryer, CPA, CA, on its board effective February 9, 2026.
  • Ryer brings 20+ years of financial leadership in pharma, biotech, and tech sectors.
  • Slassi served on the board for 4 years, contributing to PharmAla’s early-stage development.
  • Ryer’s expertise includes public market transitions and capital raising, critical as PharmAla scales.

The big picture

PharmAla’s board refresh signals a pivot from foundational research to commercial-scale operations. The addition of a seasoned financial executive suggests preparations for public market expansion or large-scale financing, critical as the psychedelics sector matures. Ryer’s background in M&A and capital raising could position PharmAla for strategic partnerships or acquisitions as it competes in the MDMA derivatives space.

What we're watching

Financial Strategy
How Ryer’s capital markets expertise will shape PharmAla’s funding strategy amid psychedelics sector volatility.
Regulatory Alignment
Whether PharmAla can maintain its 'regulatory first' approach while accelerating commercialization.
Execution Risk
The pace at which PharmAla advances ALA-002 and other IP families under new board leadership.